Sensei Biotherapeutics, Inc. 8-K

What Happened

• Sensei Biotherapeutics, Inc. (SNSE) announced its quarterly financial results for the quarter ended March 31, 2026. The company issued a press release dated May 15, 2026 and filed that release as an Exhibit (99.1) to a Form 8-K under Item 2.02 (Results of Operations and Financial Condition). The 8-K discloses that the press release contains the company’s reported quarterly results.

Key Details

• Filing: Form 8-K filed May 15, 2026 (Item 2.02: Results of Operations and Financial Condition).
• Press release: Exhibit 99.1 attached to the 8-K (press release dated May 15, 2026).
• Reporting period: Quarter ended March 31, 2026 (Q1 2026).
• The 8-K points investors to the press release for the specific financial figures and narrative.

Why It Matters

• Quarterly results (earnings, revenue, cash position, and operating expenses) can affect Sensei’s stock price and investor view of the company’s biotech development and cash runway. This Form 8-K signals the company has publicly released its latest quarterly performance; investors should read the attached press release for the detailed numbers and management commentary to assess impact on revenue, net loss, and near-term financing needs.